Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus DHAP in Relapsed CD20+ B-Cell Non-Hodgkin's Lymphoma
NCT00005601Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 2000
- Primary completion
- Jul 2003
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of rituximab in B-cell non-Hodgkin lymphoma, sponsored by Cancer and Leukemia Group B. Started Oct 2000; status: completed.
02
Drugs
rituximab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00005601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005601.